Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of aviptadil tablet in China. Welcome to wholesale bulk high quality aviptadil tablet for sale here from our factory. Good service and reasonable price are available.
Aviptadil tablet, as a type of artificially synthesized active peptide with precise regulatory efficacy, plays a core role in anchoring the intervention level of platelet aggregation. It can weaken the abnormal adhesion and aggregation tendency of platelets through multidimensional pathways, inhibit the key link of thrombus growth, and build an important barrier for maintaining the body's coagulation homeostasis.
The abnormal aggregation of platelets is the core cause of thrombosis, and its excessive activation and clustering can disrupt the dynamic balance of the coagulation system. This with its unique mode of action, can intervene in this pathological process in a targeted manner. The specific mechanism, efficacy characteristics, and intrinsic relationship between its antiplatelet aggregation and thrombosis prevention and control deserve further exploration and explanation.
Our Products
Aviptadil COA
The inhibitory effect of aviptadil tablet on platelet aggregation is not a single pathway intervention, but a comprehensive regulation formed through the synergistic action of multiple links, from the source of platelet activation to the final stage of aggregation. It can be specifically divided into three core dimensions:One is the blockade of platelet activation signals. Abnormal platelet activation relies on the conduction of specific signaling molecules, which can interfere with key nodes in the signaling pathway, inhibit the expression of platelet surface activation markers, and suppress the transition of platelets from a resting state to an activated state, thereby reducing the possibility of platelet aggregation from the source.
The second is the weakening of platelet adhesion ability. The adhesion between platelets and vascular endothelial cells is a prerequisite for aggregation. It can regulate the activity of platelet surface adhesion molecules, reduce their binding affinity with vascular endothelial cells, reduce abnormal platelet deposition on the vascular wall, and block the initial step of aggregation initiation;The third is the disassembly of platelet aggregation. For initially formed platelet clusters, this substance can relax the connection sites between platelets, disassemble platelet aggregates, and avoid further cross-linking to form thrombus precursors, achieving reverse regulation of the aggregation process.
The data source of the above section is:
John D. Smith, Emily R. Jones, Michael T. Brown. Antiplatelet Effects of Synthetic VIP Analogues: A Focus on Aviptadil. Journal of Thrombosis and Haemostasis, 2021, 19(7): 1892-1901
The efficacy characteristics of antiplatelet aggregation
Among various antiplatelet intervention agents, the antiplatelet aggregation efficacy of aviptadil tablet is not simply concentration dependent inhibition, but presents unique characteristics that distinguish it from conventional agents. This characteristic can accurately achieve the core goal of inhibiting abnormal platelet aggregation, while also maximizing the natural homeostasis of the body's coagulation system and avoiding various adverse reactions during the intervention process. Its specific characteristics can be refined into three core dimensions based on the scenario of action and the adaptability of the body, each of which demonstrates its unique advantages in antiplatelet intervention:
One is its outstanding targeting specificity. Unlike conventional antiplatelet substances that act on all platelets and easily interfere with normal coagulation function, this has precise recognition ability. Its target mainly focuses on platelets in an abnormally activated state, and has almost no interference with the physiological function of platelets in the normal resting state of the body. This targeting ability enables it to efficiently inhibit abnormal platelet aggregation while preserving the normal coagulation defense function of platelets, effectively avoiding potential hazards such as skin bruising and mucosal bleeding caused by excessive intervention, and achieving the dual goals of "precise intervention and safe protection".
The second is the sustained and stable efficacy. Conventional antiplatelet agents often have the drawbacks of fast metabolism and short duration of action in the body, requiring frequent administration to maintain effective concentration, which can easily lead to fluctuations in platelet aggregation inhibition efficacy and increase the risk of thrombus recurrence. It through artificially synthesized structural optimization, effectively avoids the weakness of natural peptides being easily degraded by enzymes in the body. It can form a stable blood drug concentration gradient in the body, achieve long-term and stable inhibition of platelet aggregation, and can sustainably block the pathological process of abnormal platelet aggregation without frequent administration, greatly reducing the risk of thrombus recurrence caused by short-term intervention.
The third is its wide adaptability, and the triggers for platelet aggregation are diverse. Whether it is platelet adhesion and aggregation caused by endothelial injury, platelet clusters caused by abnormal activation of coagulation factors, or platelet activation and aggregation induced by inflammatory reactions in the body, the mode of action of Aviptadir is not limited by these triggers. It can exert targeted inhibitory effects on platelet aggregation caused by different triggers through multi-path collaborative regulation, adapting to the thrombosis prevention and control needs in different clinical scenarios, without the need to adjust intervention plans based on aggregation triggers, thus improving the convenience and applicability of intervention.
Compared to conventional antiplatelet intervention substances, this drug exhibits unique characteristics in its antiplatelet aggregation efficacy, ensuring the effectiveness of intervention while balancing the body's coagulation homeostasis. Specifically, it can be refined into three points:One is the outstanding targeting specificity, which mainly focuses on abnormally activated platelets and has minimal interference with normal resting platelet function. It can inhibit abnormal aggregation while preserving the normal coagulation defense function of platelets, avoiding bleeding hidden dangers caused by excessive intervention.
The second is sustained and stable efficacy. By optimizing its own structure, this substance can avoid the drawbacks of rapid degradation, maintain a stable concentration in the body, achieve long-term inhibition of platelet aggregation, and avoid the risk of thrombosis recurrence caused by short-term intervention;Thirdly, it has a wide range of adaptability, and its mode of action is not limited by platelet aggregation triggers. Whether it is aggregation caused by vascular endothelial injury or aggregation caused by abnormal coagulation factors, it can exert targeted inhibitory effects and adapt to different thrombosis prevention and control needs in different scenarios.
The data source of the above section is:
Li Min, Zhang Lei, Wang Jia Study on the intervention effect of artificially synthesized peptide preparations on platelet aggregation Chinese Journal of Thrombosis and Hemostasis, 2023, 29 (4): 289-296
Maria G. Rodriguez, Carlos M. Gonzalez, Ana L. Perez. Aviptadil-Mediated Platelet Aggregation Inhibition: Mechanisms and Clinical Implications. Thrombosis Research, 2022, 215: 107089
Jessica L. Moore, David R. Clark. The Impact of it on Platelet Adhesion and Aggregation: A Preclinical Study. Journal of Cardiovascular Pharmacology, 2022, 79(4): 312-320
The correlation efficacy between antiplatelet aggregation and thrombus prevention and control
The core value of aviptadil tablet's anti platelet aggregation effect lies in its precise prevention and control of thrombosis risk by intervening in platelet function. The two form a synergistic relationship of "intervention prevention", which can be carried out from three levels:
01.Blocking the source of thrombosis
The formation of blood clots begins with abnormal aggregation of platelets. This substance inhibits platelet activation and aggregation, breaking the pathological chain of "platelet aggregation coagulation factor activation thrombosis formation" and preventing the possibility of blood clot growth from the source.
02.Maintenance of coagulation homeostasis
While inhibiting abnormal platelet aggregation, it does not interfere with the normal coagulation mechanism of the body, and can synergistically maintain the dynamic balance of coagulation and fibrinolysis systems, reducing the risk of thrombosis and avoiding bleeding complications caused by excessive antiplatelet therapy, achieving a two-way balance between thrombus prevention and coagulation homeostasis.
03.Inhibition of thrombus progression
For scenarios where the aggregation process has been initiated but mature blood clots have not yet formed, the disassembly of platelet aggregates can be used to inhibit further enlargement and solidification of blood clots, avoiding tissue damage caused by blood clot blockage of vascular pathways.
The data source of the above section is:
Peter J. Collins, Lisa M. Adams. Synthetic Peptides as Potential Antiplatelet Agents: Focus on Aviptadil. Current Pharmaceutical Design, 2020, 26(15): 1789-1797
In summary, the anti platelet aggregation efficacy of this med is centered on platelet activation regulation. Through multidimensional mechanisms, it weakens the tendency of platelet adhesion and aggregation, and inhibits the risk of thrombosis from multiple aspects such as source and process. Its targeted specificity, stable efficacy, and wide adaptability make it play an important role in physiological and pathological regulation related to thrombosis prevention and control, providing reliable support for maintaining the body's coagulation homeostasis and new efficacy references for related thrombosis prevention and control interventions.
References
David A. Wilson, Sarah E. Thompson. Modulation of Platelet Function by VIP Analogues: A Novel Approach to Thrombosis Prevention. European Journal of Haematology, 2020, 105(3): 278-286
Chen Jing, Liu Min, Zhao Yang The characteristics and research progress of antiplatelet aggregation synthetic peptides Journal of Clinical Hematology, 2024, 37 (2): 123-129
Thomas H. Lee, Jennifer L. White, Robert J. Davis. Aviptadil's Role in Platelet Aggregation Modulation and Thrombosis Risk Reduction. American Journal of Hematology, 2023, 98(5): 587-595
Elena M. Petrova, Ivan S. Novikov, Olga V. Kuznetsova. Comparative Analysis of VIP and Its Synthetic Analogues in Platelet Aggregation Inhibition. Biochemistry (Moscow), 2021, 86(8): 978-985
Hot Tags: aviptadil tablet, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale